Epidemiology and Clinical Characteristics of Non-AIDS-Defining Malignancies

  • Elizabeth Y. Chiao


Since the widespread introduction of HAART over 10 years ago, the epidemiology of HIV-related malignancies has been evolving. While the incidence and the mortality of AIDS-defining cancers (Kaposi sarcoma and non-Hodgkin lymphoma, in particular) have been decreasing, the incidence of and the mortality from non-AIDS-defining malignancies appear to be increasing. This chapter reviews the recent literature published on the epidemiology and clinical manifestations, including outcomes of non-AIDS-defining malignancies. Although HAART has improved survival from opportunistic infections and AIDS-defining malignancies; it appears that HIV-infected individuals on HAART still have an elevated incidence of certain non-AIDS malignancies (especially those that are mediated by viral oncogenesis, such as EBV and HPV). In addition, it is unclear if utilization of HAART during treatment results in equivalent survival compared to HIV-negative individuals. The focus of the chapter will be on the more common non-AIDS malignancies such as Hodgkin disease, SCCA, and lung cancer. However, the epidemiology of other non-AIDS-defining malignancies will also be discussed including skin cancer, head and neck cancer, conjunctival cancer, testicular cancer, leiomyosarcoma, hepatocellular carcinoma, breast cancer, multiple myeloma, leukemia, colon cancer, and prostate cancer.


Human Immunodeficiency Virus Human Immunodeficiency Virus Infection Hodgkin Lymphoma Human Immunodeficiency Virus Disease Hodgkin Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. American Cancer Society (2000). Cancer Facts and Figures, (Atlanta, GA: American Cancer Society).Google Scholar
  2. Agurs-Collins, T., Kim, K. S., et al. (1998). Plasma lipid alterations in African–American women with breast cancer. J Cancer Res Clin Oncol 124(3–4), 186–190.PubMedCrossRefGoogle Scholar
  3. Allardice, G. M., Hole, D. J., et al. (2003). Incidence of malignant neoplasms among HIV-infected persons in Scotland. Br J Cancer 89(3), 505–507.PubMedCrossRefGoogle Scholar
  4. Alshafie, M. T., Donaldson, B., et al. (1997). Human immunodeficiency virus and lung cancer. Br J Surg 84(8), 1068–1071.PubMedCrossRefGoogle Scholar
  5. Arnott, S. J., Cunningham, D., et al. (1996). Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet 348(9034), 1049–1054.CrossRefGoogle Scholar
  6. Beckmann, A. M., Daling, J. R., et al. (1989). Human papillomavirus infection and anal cancer. Int J Cancer 43(6), 1042–1049.PubMedCrossRefGoogle Scholar
  7. Berenguer, J., Miralles, P., et al. (2008). Characteristics and outcome of AIDS-related Hodgkin lymphoma before and after the introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 47(4), 422–428.PubMedCrossRefGoogle Scholar
  8. Berretta, M., Cinelli, R., et al. (2003). Therapeutic approaches to AIDS-related malignancies. Oncogene 22(42), 6646–6659.PubMedCrossRefGoogle Scholar
  9. Biggar, R. J., Curtis, R. E., et al. (1994). Risk of other cancers following Kaposi’s sarcoma: relation to acquired immunodeficiency syndrome. Am J Epidemiol 139(4), 362–368.PubMedGoogle Scholar
  10. Biggar, R. J., Jaffe, E. S., et al. (2006). Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood 108(12), 3786–3791.PubMedCrossRefGoogle Scholar
  11. Blazy, A., Hennequin, C., et al. (2005). Anal carcinomas in HIV-positive patients: high-dose chemoradiotherapy is feasible in the era of highly active antiretroviral therapy. Dis Colon Rectum 48(6), 1176–1181.PubMedCrossRefGoogle Scholar
  12. Bosch, F. X., Manos, M. M., et al. (1995). Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group. J Natl Cancer Inst 87(11), 796–802.PubMedCrossRefGoogle Scholar
  13. Bottomley, D. M., Aqel, N., et al. (1996). Epidermoid anal cancer in HIV infected patients. Clin Oncol (R Coll Radiol) 8(5), 319–322.CrossRefGoogle Scholar
  14. Bower, M., Powles, T., Nelson, M., et al. (2003). HIV-related lung cancer in the era of highly active antiretroviral therapy. AIDS 17, 371–375.PubMedCrossRefGoogle Scholar
  15. Bower, M., Powles, T., et al. (2004). HIV-associated anal cancer: has highly active antiretroviral therapy reduced the incidence or improved the outcome? J Acquir Immune Defic Syndr 37(5), 1563–1565.PubMedCrossRefGoogle Scholar
  16. Chang, G. J., Berry, J. M., et al. (2002). Surgical treatment of high-grade anal squamous intraepithelial lesions: a prospective study. Dis Colon Rectum 45(4), 453–458.PubMedCrossRefGoogle Scholar
  17. Chaturvedi, A. K., Mbulaiteye, S. M., et al. (2008). Underestimation of relative risks by standardized incidence ratios for AIDS-related cancers. Ann Epidemiol 18(3), 230–234.PubMedCrossRefGoogle Scholar
  18. Chiao, E. Y., Giordano, T. P., et al. (2006). Screening HIV-infected individuals for anal cancer precursor lesions: a systematic review. Clin Infect Dis 43(2), 223–233.PubMedCrossRefGoogle Scholar
  19. Chiao, E. Y., Giordano, T. P., et al. (2008). Human immunodeficiency virus-associated squamous cell cancer of the anus: epidemiology and outcomes in the highly active antiretroviral therapy era. J Clin Oncol 26(3), 474–479.PubMedCrossRefGoogle Scholar
  20. Chiu, H. M., Lin, J. T., et al. (2008). Elevation of C-reactive protein level is associated with synchronous and advanced colorectal neoplasm in men. Am J Gastroenterol 103(9), 2317–2325.PubMedCrossRefGoogle Scholar
  21. Clark, M. A., Hartley, A., et al. (2004). Cancer of the anal canal. Lancet Oncol 5(3), 149–157.PubMedCrossRefGoogle Scholar
  22. Cleator, S., Fife, K., et al. (2000). Treatment of HIV-associated invasive anal cancer with combined chemoradiation. Eur J Cancer 36(6), 754–758.PubMedCrossRefGoogle Scholar
  23. Clifford, G. M., Polesel, J., et al. (2005). Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 97(6), 425–432.PubMedCrossRefGoogle Scholar
  24. Cocchi, V., Carretti, D., et al. (1997). Intralaboratory quality assurance in cervical/vaginal cytology: evaluation of intercytologist diagnostic reproducibility. Diagn Cytopathol 16(1), 87–92.PubMedCrossRefGoogle Scholar
  25. Cooksley, C. D., Hwang, L. Y., et al. (1999). HIV-related malignancies: community-based study using linkage of cancer registry and HIV registry data. Int J STD AIDS 10(12), 795–802.PubMedCrossRefGoogle Scholar
  26. Cress, R. D., and Holly, E. A. (2003). Incidence of anal cancer in California: increased incidence among men in San Francisco, 1973–1999. Prev Med 36(5), 555–560.PubMedCrossRefGoogle Scholar
  27. Dal Maso, L., Franceschi, S., et al. (2003a). Risk of cancer in persons with AIDS in Italy, 1985–1998. Br J Cancer 89(1), 94–100.PubMedCrossRefGoogle Scholar
  28. Dal Maso, L., Polesel, J., et al. (2003b). Lung cancer in persons with AIDS in Italy, 1985–1998. AIDS 17(14), 2117–2119.PubMedCrossRefGoogle Scholar
  29. Daling, J. R., Weiss, N. S., et al. (1987). Sexual practices, sexually transmitted diseases, and the incidence of anal cancer. N Engl J Med 317(16), 973–977.PubMedCrossRefGoogle Scholar
  30. Darragh, T., Birdson, G., et al. (2004). Chapter 8: Anal–Rectal Cytology, (New York, NY: Springer).Google Scholar
  31. Diaz, P. T., King, M. A., et al. (2000). Increased susceptibility to pulmonary emphysema among HIV-seropositive smokers. Ann Intern Med 132(5), 369–372.PubMedGoogle Scholar
  32. Doci, R., Zucali, R., et al. (1992). Combined chemoradiation therapy for anal cancer. A report of 56 cases. Ann Surg 215(2), 150–156.PubMedCrossRefGoogle Scholar
  33. Doweiko, J., Dezube, B. J., et al. (2004). Unusual sites of Hodgkin’s lymphoma: CASE 1. HIV-associated Hodgkin’s lymphoma of the stomach. J Clin Oncol 22(20), 4227–4228.PubMedCrossRefGoogle Scholar
  34. El-Sadr, W. M., Lundgren, J. D., et al. (2006). CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 355(22), 2283–2296.PubMedCrossRefGoogle Scholar
  35. Eltom, M. A., Jemal, A., et al. (2002). Trends in Kaposi’s sarcoma and non-Hodgkin’s lymphoma incidence in the United States from 1973 through 1998. J Natl Cancer Inst 94(16), 1204–1210.PubMedCrossRefGoogle Scholar
  36. Engels, E. A. (2001). Human immunodeficiency virus infection, aging, and cancer. J Clin Epidemiol 54(Suppl 1), S29–S34.PubMedCrossRefGoogle Scholar
  37. Engels, E. A., Brock, M. V., et al. (2006). Elevated incidence of lung cancer among HIV-infected individuals. J Clin Oncol 24(9), 1383–1388.PubMedCrossRefGoogle Scholar
  38. Errante, D., Gabarre, J., et al. (1999). Hodgkin’s disease in 35 patients with HIV infection: an experience with epirubicin, bleomycin, vinblastine and prednisone chemotherapy in combination with antiretroviral therapy and primary use of G-CSF. Ann Oncol 10(2), 189–195.PubMedCrossRefGoogle Scholar
  39. Errante, D., Tirelli, U., et al. (1994). Combined antineoplastic and antiretroviral therapy for patients with Hodgkin’s disease and human immunodeficiency virus infection. A prospective study of 17 patients. The Italian Cooperative Group on AIDS and Tumors (GICAT). Cancer 73(2), 437–444.PubMedCrossRefGoogle Scholar
  40. Flam, M., John, M., et al. (1996). Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 14(9), 2527–2539.PubMedGoogle Scholar
  41. Franceschi, S., Dal Maso, L., et al. (1998). Risk of cancer other than Kaposi’s sarcoma and non-Hodgkin’s lymphoma in persons with AIDS in Italy. Cancer and AIDS Registry Linkage Study. Br J Cancer 78(7), 966–970.PubMedCrossRefGoogle Scholar
  42. Friis-Moller, N., Sabin, C. A., et al. (2003). Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 349(21), 1993–2003.PubMedCrossRefGoogle Scholar
  43. Frisch, M., Biggar, R. J., et al. (2000). Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 92(18), 1500–1510.PubMedCrossRefGoogle Scholar
  44. Frisch, M., Biggar, R., et al. (2001). Association of cancer with AIDS-related immunosuppression in adults. JAMA 285(13), 1736–1745.PubMedCrossRefGoogle Scholar
  45. Frisch, M., Smith, E., et al. (2003). Cancer in a population-based cohort of men and women in registered homosexual partnerships. Am J Epidemiol 157(11), 966–972.PubMedCrossRefGoogle Scholar
  46. Gallagher, B., Zhengyan, W., et al. (2001). Cancer incidence in New York State acquired immunodeficiency syndrome patients. Am J Epidemiol 154, 544–556.PubMedCrossRefGoogle Scholar
  47. Gerard, J. P., Ayzac, L., et al. (1998). Treatment of anal canal carcinoma with high dose radiation therapy and concomitant fluorouracil–cisplatinum. Long-term results in 95 patients. Radiother Oncol 46(3), 249–256.PubMedCrossRefGoogle Scholar
  48. Gerard, L., Galicier, L., et al. (2003). Improved survival in HIV-related Hodgkin’s lymphoma since the introduction of highly active antiretroviral therapy. AIDS 17(1), 81–87.PubMedCrossRefGoogle Scholar
  49. Glaser, S. L., Clarke, C. A., et al. (2003). Population-based patterns of human immunodeficiency virus-related Hodgkin lymphoma in the Greater San Francisco Bay Area, 1988–1998. Cancer 98(2), 300–309.PubMedCrossRefGoogle Scholar
  50. Goedert, J. J., Cote, T. R., et al. (1998). Spectrum of AIDS-associated malignant disorders. Lancet 351(9119), 1833–1839.PubMedCrossRefGoogle Scholar
  51. Goldie, S. J., Kuntz, K. M., et al. (1999). The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men. JAMA 281(19), 1822–1829.PubMedCrossRefGoogle Scholar
  52. Goldstone, S. E., Kawalek, A. Z., et al. (2005). Infrared coagulator: a useful tool for treating anal squamous intraepithelial lesions. Dis Colon Rectum 48(5), 1042–1054.PubMedCrossRefGoogle Scholar
  53. Goodwin, P. J., Boyd, N. F., et al. (1997). Elevated levels of plasma triglycerides are associated with histologically defined premenopausal breast cancer risk. Nutr Cancer 27(3), 284–292.PubMedCrossRefGoogle Scholar
  54. Graham, B. D., Jetmore, A. B., et al. (2005). Topical 5-fluorouracil in the management of extensive anal Bowen’s disease: a preferred approach. Dis Colon Rectum 48(3), 444–450.PubMedCrossRefGoogle Scholar
  55. Grulich, A. E., Li, Y., et al. (2002). Rates of non-AIDS-defining cancers in people with HIV infection before and after AIDS diagnosis. AIDS 16(8), 1155–1161.PubMedCrossRefGoogle Scholar
  56. Grulich, A., Wan, X., et al. (1999). Risk of cancer in people with AIDS. AIDS 13(7), 839–843.PubMedCrossRefGoogle Scholar
  57. Grulich, A. E., van Leeuwen, M. T., et al. (2007). Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 370(9581), 59–67.PubMedCrossRefGoogle Scholar
  58. Hajjar, M., Lacoste, D., et al. (1992). Non-acquired immune deficiency syndrome-defining malignancies in a hospital-based cohort of human immunodeficiency virus-infected patients: Bordeaux, France, 1985–1991. Groupe d’Epidemiologie clinique du SIDA en aquitaine. J Natl Cancer Inst 84(20), 1593–1595.PubMedCrossRefGoogle Scholar
  59. Hakimian, R., Fang, H., et al. (2007). Lung cancer in HIV-infected patients in the era of highly active antiretroviral therapy. J Thorac Oncol 2(4), 268–272.PubMedCrossRefGoogle Scholar
  60. Hartmann, P., Rehwald, U., et al. (2003). BEACOPP therapeutic regimen for patients with Hodgkin’s disease and HIV infection. Ann Oncol 14(10), 1562–1569.PubMedCrossRefGoogle Scholar
  61. Herida, M., Mary-Krause, M., et al. (2003). Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol 21(18), 3447–3453.PubMedCrossRefGoogle Scholar
  62. Hocht, S., Wiegel, T., et al. (1997). Low acute toxicity of radiotherapy and radiochemotherapy in patients with cancer of the anal canal and HIV-infection. Acta Oncol 36(8), 799–802.PubMedCrossRefGoogle Scholar
  63. Hoffman, R., Welton, M. L., et al. (1999). The significance of pretreatment CD4 count on the outcome and treatment tolerance of HIV-positive patients with anal cancer. Int J Radiat Oncol Biol Phys 44(1), 127–131.PubMedCrossRefGoogle Scholar
  64. Hoffmann, C., Chow, K. U., et al. (2004). Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin’s disease. Br J Haematol 125(4), 455–462.PubMedCrossRefGoogle Scholar
  65. Jephcott, C. R., Paltiel, C., et al. (2004). Quality of life after non-surgical treatment of anal carcinoma: a case control study of long-term survivors. Clin Oncol (R Coll Radiol) 16(8), 530–535.CrossRefGoogle Scholar
  66. John, M., Flam, M., et al. (1996). Ten-year results of chemoradiation for anal cancer: focus on late morbidity. Int J Radiat Oncol Biol Phys 34(1), 65–69.PubMedCrossRefGoogle Scholar
  67. Johnson, L. G., Madeleine, M. M., et al. (2004). Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973–2000. Cancer 101(2), 281–288.PubMedCrossRefGoogle Scholar
  68. Kosary, C., Reiss, L., et al. (1995). SEER Cancer Statistics Review, 1973–1992: Tables and Graphs, (Bethesda, MD: NIH Publication, 96-2789).Google Scholar
  69. Kreuter, A., Hochdorfer, B., et al. (2004). Treatment of anal intraepithelial neoplasia in patients with acquired HIV with imiquimod 5% cream. J Am Acad Dermatol 50(6), 980–981.PubMedCrossRefGoogle Scholar
  70. Kuller, L. H., Tracy, R., et al. (2008). Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 5(10), e203.PubMedCrossRefGoogle Scholar
  71. Lewden, C., Salmon, D., et al. (2005). Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol 34(1), 121–130.PubMedCrossRefGoogle Scholar
  72. Louie, J. K., Hsu, L. C., et al. (2002). Trends in causes of death among persons with acquired immunodeficiency syndrome in the era of highly active antiretroviral therapy, San Francisco, 1994–1998. J Infect Dis 186(7), 1023–1027.PubMedCrossRefGoogle Scholar
  73. Mbulaiteye, S., Biggar, R., et al. (2003). Immune deficiency and risk for malignancy among persons with AIDS. J Acquir Immune Defic Syndr 32(5), 527–533.PubMedCrossRefGoogle Scholar
  74. McGinnis, K., Skanderson, M., et al. (2002). Pre and post HAART cancer incidence among HIV positive veterans. Int Conf AIDS.Google Scholar
  75. Melbye, M., Rabkin, C., et al. (1994). Changing patterns of anal cancer incidence in the United States, 1940–1989. Am J Epidemiol 139(8), 772–780.PubMedGoogle Scholar
  76. Monforte, A., Abrams, D., et al. (2008). HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS 22(16), 2143–2153.PubMedCrossRefGoogle Scholar
  77. Myerson, R. J., Kong, F., et al. (2001). Radiation therapy for epidermoid carcinoma of the anal canal, clinical and treatment factors associated with outcome. Radiother Oncol 61(1), 15–22.PubMedCrossRefGoogle Scholar
  78. New York State AIDS Malignancy Consortium (2004). Criteria for the Medical Care of Adults with HIV Infection. pp. 1–18, (New York, NY: New York State Department of Health AIDS Institute).Google Scholar
  79. Northover, J. M. (1991). Epidermoid cancer of the anus – the surgeon retreats. J R Soc Med 84(7), 389–390.PubMedGoogle Scholar
  80. Oehler-Janne, C., Huguet, F., et al. (2008). HIV-specific differences in outcome of squamous cell carcinoma of the anal canal: a multicentric cohort study of HIV-positive patients receiving highly active antiretroviral therapy. J Clin Oncol 26(15), 2550–2557.PubMedCrossRefGoogle Scholar
  81. Olivero, O. A., Tejera, A. M., et al. (2005). Zidovudine induces S-phase arrest and cell cycle gene expression changes in human cells. Mutagenesis 20(2), 139–146.PubMedCrossRefGoogle Scholar
  82. Palefsky, J. M., Holly, E. A., et al. (1997). Anal cytology as a screening tool for anal squamous intraepithelial lesions. J Acquir Immune Defic Syndr Hum Retrovirol 14(5), 415–422.PubMedCrossRefGoogle Scholar
  83. Palefsky, J. M., Holly, E. A., et al. (2001). Effect of highly active antiretroviral therapy on the natural history of anal squamous intraepithelial lesions and anal human papillomavirus infection. J Acquir Immune Defic Syndr 28(5), 422–428.PubMedGoogle Scholar
  84. Palefsky, J. M., Holly, E. A., et al. (2002). Effect of HAART on incidence of anal intraepithelial neoplasia grade 3 among HIV-positive men who have sex with men. Proceedings of the 14th International Conference on AIDS, Barcelona, Spain.Google Scholar
  85. Parker, M., and Leveno, D. (1998). AIDS-related bronchogenic carcinoma: factor fiction. Chest 113, 154–161.PubMedCrossRefGoogle Scholar
  86. Patel, P., Hanson, D. L., et al. (2008). Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992–2003. Ann Intern Med 148(10), 728–736.PubMedGoogle Scholar
  87. Patel, P., Tong, T., et al. (2004). Incidence of non-AIDS-defining malignancies in the HIV outpatient study (HOPS). Proceedings of the 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA.Google Scholar
  88. Peddada, A. V., Smith, D. E., et al. (1997). Chemotherapy and low-dose radiotherapy in the treatment of HIV-infected patients with carcinoma of the anal canal. Int J Radiat Oncol Biol Phys 37(5), 1101–1105.PubMedCrossRefGoogle Scholar
  89. Petruckevitch, A., Del Amo, J., et al. (1999). Risk of cancer in patients with HIV disease. London African HIV/AIDS Study Group. Int J STD AIDS 10(1), 38–42.PubMedCrossRefGoogle Scholar
  90. Pitcher, M. E., Davidson, T. I., et al. (1994). Post irradiation sarcoma of soft tissue and bone. Eur J Surg Oncol 20(1), 53–56.PubMedGoogle Scholar
  91. Powles, T., Nelson, M., et al. (2003). HIV-related lung cancer – a growing concern? Int J STD AIDS 14(10), 647–651.PubMedCrossRefGoogle Scholar
  92. Powles, T., Powles, J., et al. (2004). Head and neck cancer in patients with human immunodeficiency virus-1 infection: incidence, outcome and association with Epstein–Barr virus. J Laryngol Otol 118(3), 207–212.PubMedCrossRefGoogle Scholar
  93. Powles, T., Thirwell, C., et al. (2003). Does HIV adversely influence the outcome in advanced non-small-cell lung cancer in the era of HAART? Br J Cancer 89(3), 457–459.PubMedCrossRefGoogle Scholar
  94. Ree, H. J., Strauchen, J. A., et al. (1991). Human immunodeficiency virus-associated Hodgkin’s disease. Clinicopathologic studies of 24 cases and preponderance of mixed cellularity type characterized by the occurrence of fibrohistiocytoid stromal cells. Cancer 67(6), 1614–1621.PubMedCrossRefGoogle Scholar
  95. Remick, S. C. (1996). Non-AIDS-defining cancers. Hematol Oncol Clin North Am 10(5), 1203–1213.PubMedCrossRefGoogle Scholar
  96. Rubio, R. (1994). Hodgkin’s disease associated with human immunodeficiency virus infection. A clinical study of 46 cases. Cooperative study group of malignancies associated with HIV infection of Madrid. Cancer 73(9), 2400–2407.PubMedCrossRefGoogle Scholar
  97. Schreier, L. E., Berg, G. A., et al. (1999). Lipoprotein alterations, abdominal fat distribution and breast cancer. Biochem Mol Biol Int 47(4), 681–690.PubMedGoogle Scholar
  98. Seaberg, E., Kingsley, L., et al. (2002). The impact of HAART on cancer incidence in the multicenter AIDS cohort study (MACS). Int Conf AIDS.Google Scholar
  99. Serraino, D., Boschini, A., et al. (2000). Cancer risk among men with, or at risk of, HIV infection in Southern Europe. AIDS 14(5), 553–559.PubMedCrossRefGoogle Scholar
  100. Silverberg, M. J., Neuhaus, J., et al. (2007). Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS 21(14), 1957–1963.PubMedCrossRefGoogle Scholar
  101. Spina, M., Berretta, M., et al. (2003). Hodgkin’s disease in HIV. Hematol Oncol Clin North Am 17(3), 843–858.PubMedCrossRefGoogle Scholar
  102. Spina, M., Gabarre, J., et al. (2002). Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection. Blood 100(6), 1984–1988.PubMedCrossRefGoogle Scholar
  103. Spina, M., Sandri, S., et al. (1999a). Hodgkin’s disease in HIV-infected individuals. Curr Opin Oncol 11(6), 522–526.PubMedCrossRefGoogle Scholar
  104. Spina, M., Vaccher, E., et al. (1999b). Neoplastic complications of HIV infection. Ann Oncol 10(11), 1271–1286.PubMedCrossRefGoogle Scholar
  105. Sridar, S., Flores, M., et al. (1992). Lung cancer in patients with human immunodeficiency virus infection compared with historic control subjects. Chest 102, 1704–1708.CrossRefGoogle Scholar
  106. Stadler, R. F., Gregorcyk, S. G., et al. (2004). Outcome of HIV-infected patients with invasive squamous-cell carcinoma of the anal canal in the era of highly active antiretroviral therapy. Dis Colon Rectum 47(8), 1305–1309.PubMedCrossRefGoogle Scholar
  107. Stoler, M. H., and Schiffman, M. (2001). Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL triage study. JAMA 285(11), 1500–1505.PubMedCrossRefGoogle Scholar
  108. Tirelli, U., Errante, D., et al. (1995a). Hodgkin’s disease and human immunodeficiency virus infection: clinicopathologic and virologic features of 114 patients from the Italian Cooperative Group on AIDS and Tumors. J Clin Oncol 13(7), 1758–1767.PubMedGoogle Scholar
  109. Tirelli, U., Spina, M., et al. (2000). Lung carcinoma in 36 patients with human immunodeficiency virus infection. The Italian Cooperative Group on AIDS and Tumors. Cancer 88(3), 563–569.PubMedCrossRefGoogle Scholar
  110. Tirelli, U., Vaccher, E., et al. (1995b). CD30 (Ki-1)-positive anaplastic large-cell lymphomas in 13 patients with and 27 patients without human immunodeficiency virus infection: the first comparative clinicopathologic study from a single institution that also includes 80 patients with other human immunodeficiency virus-related systemic lymphomas. J Clin Oncol 13(2), 373–380.PubMedGoogle Scholar
  111. Tsilidis, K. K., Branchini, C., et al. (2008). C-reactive protein and colorectal cancer risk: a systematic review of prospective studies. Int J Cancer 123(5), 1133–1140.PubMedCrossRefGoogle Scholar
  112. Uccini, S., Monardo, F., et al. (1989). High frequency of Epstein–Barr virus genome in HIV-positive patients with Hodgkin’s disease. Lancet 1(8652), 1458.PubMedCrossRefGoogle Scholar
  113. Vaccher, E., Spina, M., et al. (2001). Clinical aspects and management of Hodgkin’s disease and other tumours in HIV-infected individuals. Eur J Cancer 37(10), 1306–1315.PubMedCrossRefGoogle Scholar
  114. Vyzula, R. (1996). Lung cancer in patients with HIV-infection. Lung Cancer 15, 325–339.PubMedCrossRefGoogle Scholar
  115. White, C. S., Haramati, L. B., et al. (1995). Carcinoma of the lung in HIV-positive patients: findings on chest radiographs and CT scans. AJR Am J Roentgenol 164(3), 593–597.PubMedGoogle Scholar
  116. Wilkin, T. J., Palmer, S., et al. (2004). Anal intraepithelial neoplasia in heterosexual and homosexual HIV-positive men with access to antiretroviral therapy. J Infect Dis 190(9), 1685–1691.PubMedCrossRefGoogle Scholar
  117. Wistuba, I., Behrens, C., et al. (1998). Comparison of molecular changes in lung cancers in HIV-positive and HIV-indeterminate subjects. JAMA 279, 1154–1559.CrossRefGoogle Scholar
  118. Woodhouse, S. L., Stastny, J. F., et al. (1999). Interobserver variability in subclassification of squamous intraepithelial lesions: results of the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology. Arch Pathol Lab Med 123(11), 1079–1084.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Department of Medicine, Sections of Infectious Diseases and Health Services ResearchBaylor College of MedicineHoustonUSA
  2. 2.Houston VA Medical Center (152)HoustonUSA
  3. 3.Houston Center for Quality of Care and Utilization StudiesHoustonUSA

Personalised recommendations